Mersana Therapeutics (MRSN) said Friday that the US Food and Drug Administration recently granted an additional Fast Track designation to XMT-1660 for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease, including triple-negative breast cancer, who have received a prior topoisomerase-1 inhibitor antibody-drug conjugate, the company said.
The FDA previously granted the drug Fast Track designation for the treatment of adult patients with advanced or metastatic recurrent triple-negative breast cancer.
The company also said that the World Health Organization has approved emiltatug ledadotin as XMT-1660's international nonproprietary name.
Shares of the company were up more than 15% in Friday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。